+183%

est. 2Y upside i

HealthcareSeries A

Robotic human cell manufacturing

Rank

#99

Sector

Biotechnology

Est. Liquidity

~4Y

Data Quality

Data: Low

Mytos offers a high-risk/high-reward equity opportunity.

Last updated: July 19, 2026

Bull (20%)+400%

Mytos capitalizes on IPOs in cell therapy CDMO, achieving 8x revenue multiple on $10M revenue, yielding $80M exit. Common stock returns 400% after 20% dilution and preference stack.

Base (45%)+307%

Revenue grows to $10M, multiple converges to 5x, exit $50M. Common sees 307% upside after dilution, but preference overhang limits upside.

Bear (35%)-100%

Revenue stalls or competition prevails, exit $20M below $29.8M preference, common worthless (-100%).

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Funding Intensity

76400%

Total funding of $29.8M exceeds current valuation of $11.7M, giving preferred stock a 2.55x liquidation preference overhang. Common stock is out of the money.

Dilution Risk

high

With $19M Series A in late 2023, runway likely limited; probability of a down round or significant dilution within 24 months is high.

Secondary Liquidity

none

No secondary market data indicates limited liquidity for employee equity.

Any — 1 role

Biology — 1 role

CDMO — 1 role

Operations — 1 role

Product — 1 role

View all 8 open roles at Mytos →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Mytos's data — designed to show you've done your homework.

  • 1

    “How does Mytos plan to achieve GMP compliance at scale and what are the regulatory timelines for its current partnerships?”

  • 2

    “What is the company's revenue growth trajectory and how do you expect to expand beyond the current 5 customers?”

  • 3

    “Given the high capital intensity, what is the planned next financing round and how does the cap table affect employee equity?”

Community

Valuation Sentiment

Our model estimates +183% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.